Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.

Stine K ChristensenMette L WintherIda J LaursenFreja S MadsenCarsten Brink Thomas H Brix Eva EllebaekInge Marie SvaneFrederikke S HansenCharlotte HaslundOlivia K LaursenHenrik SchmidtIda D LarsenLars BastholtChristina Halgaard Bruvik Ruhlmann

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2024)

IrTAE is a common side effect to PD-1 inhibitors primarily occurring within the first 3 months, with a high risk of persistency. Female sex is a strong predictive factor. IrTAE was not associated with improved clinical outcome.

Keyphrases

early stage
quality improvement
prognostic factors
skin cancer
drug induced
basal cell carcinoma